Hg announces a partial sale of Intelerad
Hg, the Manager of HgCapital Trust plc ("HGT"), today announces that it has agreed a partial sale of Intelerad, a leading global provider of enterprise medical imaging solutions, to TA Associates, a leading global growth private equity firm. Hg, a leading software and services investor, will retain a significant position in the business.
The terms of the transaction have not been disclosed. The transaction is expected to close in the third quarter of 2022 pending customary regulatory approval.
HGT, whose shares are listed on the London Stock Exchange, gives private and institutional investors the opportunity to participate in all Hg's investments.
This transaction values HGT's investment in Intelerad at approximately £87.1 million. This would represent an uplift of £10.8 million (14% or 2.4 pence per share) over the carrying value of £76.3 million in the Net Asset Value ("NAV") of HGT at 31 March 2022.
Note that these figures only relate to HgCapital Trust's share of Hg's overall investment in Intelerad.
Based on the 31 March 2022 reported NAV, the pro-forma NAV of the Trust is expected to be £2.1 billion (or 458.3 pence per share). HGT's available liquid resources, which includes the undrawn bank facility of £250 million for future deployment (including all announced transactions) is estimated to be £482 million (23% of the 31 March 2022 NAV of £2.1 billion).
HGT will be releasing the June 2022 interim results on the 12th September 2022.
Intelerad Announces Significant Investment from TA to Accelerate Growth
TA joins Hg and ST6 in supporting Intelerad to advance clinical efficiency and patient care through innovative medical imaging technology.
RALEIGH, NC and MONTREAL, CANADA, July 14, 2022 - Intelerad, a leading global provider of enterprise medical imaging solutions, today announced that TA Associates ("TA"), a leading global growth private equity firm, has signed a definitive agreement to make a growth investment in the company. TA joins Intelerad's majority investor, Hg, a leading software and services investor, and ST6, a highly experienced team of software operating executives and minority investor. The transaction is expected to close in the third quarter of 2022 pending customary regulatory approval.
"We're excited to welcome TA as a partner on our continued journey to improve healthcare through innovative technology," said Mike Lipps, CEO of Intelerad. "With their deep industry knowledge and experience scaling healthcare technology companies, the addition of TA and continued support from Hg will help Intelerad to significantly advance our growth strategy and value to customers."
Founded in 1999, Intelerad provides medical imaging software and enterprise workflow solutions to healthcare providers worldwide. Headquartered in Raleigh, NC and Montreal, Canada, the company serves nearly 2,000 customers around the world, including radiology groups, outpatient imaging centers, hospitals and healthcare systems, managing over 50 billion medical images and empowering more than 300,000 clinicians, who collectively read over 140 million exams on Intelerad's platform each year.
"We have followed Intelerad for several years and continue to be impressed by its differentiated solutions, strong growth and leadership position," said Mark Carter, a Managing Director at TA. "Building on its momentum in the sector, we believe Intelerad is well positioned to further strengthen and expand its suite of solutions. We are supportive of Intelerad's vision and excited to join the team as it enters the next phase of its growth journey," added Ethan Liebermann, a Managing Director at TA.
Hector Guinness and JB Brian, Partners at Hg, said, "Intelerad has built a platform that is making a difference in patient care by enabling significant efficiencies and speed-to-results for healthcare organizations. We're proud to have supported the Intelerad team, who have achieved significant progress in such a short period, doubling the size of the business in two years."
Globally, demand for scalable imaging and workflow solutions continues to increase as imaging sites consolidate and the volume of procedures grows, placing greater pressure on productivity. Intelerad's growth strategy is to provide customers with one of the most scalable imaging platforms in the world, and as a result, Intelerad customers are already benefiting from an expanded suite of solutions, best-in-class flexibility, and increased support which will enable them to drive clinical efficiency and focus on providing enhanced patient care.
"The COVID-19 pandemic has intensified the challenges facing this industry and accelerated the demand to improve patient care," said Mark Friedman, Intelerad Executive Chairman and Managing Director at ST6. "Intelerad has recognized this need and is actively working to make its customers more productive, more agile, and more responsive. We look forward to partnering with TA to promote organic development and pursue strategic growth opportunities. The new investment from TA will help Intelerad further deliver the critical value that our customers need right now."
Kirkland & Ellis is providing legal counsel to TA. Skadden, Arps, Slate, Meagher & Flom LLP, DLA and McCarthy Tétrault LLP are providing legal counsel to Hg and Intelerad.
For further details:
Hg
Tom Eckersley +44 (0)208 148 5401
HGT
Laura Dixon +44 (0)20 8396 0930
Brunswick
Azadeh Varzi +44 (0)207 404 5959
Hg@brunswickgroup.com
About HgCapital Trust plc
HgCapital Trust plc, whose shares are listed on the London Stock Exchange (ticker: HGT.L), gives investors exposure through a liquid vehicle to a portfolio of high-growth private companies in the software and services sector. The selection of new investments and creation of value in these businesses are managed by Hg, an experienced and well-resourced private equity firm with a long-term track record of delivering superior risk-adjusted returns for its investors. For further details, please see www.hgcapitaltrust.com.
The contents of the Hg, HgCapital Trust, TA Associates and Intelerad websites are not incorporated into, and do not form part of, this announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund